Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Regeneron Pharmaceuticals (NQ: REGN )

748.14 UNCHANGED
Streaming Delayed Price Updated: 4:00 PM EDT, Jun 6, 2023 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Press Releases about Regeneron Pharmaceuticals

< Previous 1 2 Next >
Updated Linvoseltamab (BCMAxCD3) Data from Pivotal Trial Demonstrates Early, Deep and Durable Responses in Patients with Heavily Pre-treated Multiple Myeloma
From Regeneron Pharmaceuticals, Inc.
Via GlobeNewswire
Fianlimab (LAG-3 inhibitor) Combined with Libtayo® (cemiplimab) Shows Clinically Meaningful and Durable Tumor Responses Across Key Advanced Melanoma Patient Populations
From Regeneron Pharmaceuticals, Inc.
Via GlobeNewswire
Dupixent® (dupilumab) Late-breaking Phase 3 COPD Results Presented at ATS and Simultaneously Published in the New England Journal of Medicine
From Regeneron Pharmaceuticals, Inc.
Via GlobeNewswire
Regeneron Pharmaceuticals Inc. (NASDAQ: REGN) is a Leading Gainer in 5/19 Morning Trading
Via Investor Brand Network
Regeneron Pharmaceuticals (NASDAQ: REGN) is a Leading Gainer in 3/23 Morning Trading
Via Investor Brand Network
High School Scientists and Engineers Win Nearly $9 Million at the Regeneron International Science and Engineering Fair 2023
$75,000 Top Award Goes to 17-year-old Kaitlyn Wang for breakthrough innovation to accelerate exoplanet discovery in the largest international STEM competition for teens 
From Regeneron Pharmaceuticals, Inc.
Via GlobeNewswire
Regeneron Announces Investor Conference Presentations
From Regeneron Pharmaceuticals, Inc.
Via GlobeNewswire
Regeneron Applauds Supreme Court’s Unanimous Opinion Striking Down Amgen’s PCSK9 Patent Claims and Supporting Scientific Innovation
From Regeneron Pharmaceuticals, Inc.
Via GlobeNewswire
Regeneron Beats Q1 Views, But Stock Drops On Weak Eye Med Sales
Regeneron reported better-than-expected Q1 earnings and revenue, but its Eylea sales fell, losing ground to Roche's newly launched Vabysmo. 
Via MarketBeat
Regeneron Reports First Quarter 2023 Financial and Operating Results
From Regeneron Pharmaceuticals, Inc.
Via GlobeNewswire
Regeneron to Highlight New and Updated Clinical Data at ASCO Showcasing Breadth of Cancer Research
From Regeneron Pharmaceuticals, Inc.
Via GlobeNewswire
Alnylam and Regeneron Report Positive Interim Phase 1 Clinical Data on ALN-APP, an Investigational RNAi Therapeutic for Alzheimer’s Disease and Cerebral Amyloid Angiopathy
From Alnylam Pharmaceuticals, Inc.
Via Business Wire
Regeneron and Alnylam Report Positive Interim Phase 1 Clinical Data on ALN-APP, an Investigational RNAi Therapeutic for Alzheimer’s Disease and Cerebral Amyloid Angiopathy
From Regeneron Pharmaceuticals, Inc.
Via GlobeNewswire
Regeneron Announces Retirement of Board Chair, Dr. P. Roy Vagelos, Accomplished Physician-Businessman and Industry Luminary
Dr. Leonard S. Schleifer and Dr. George D. Yancopoulos to become Co-Chairs of the Board and Christine A. Poon to be named Lead Independent Director 
From Regeneron Pharmaceuticals, Inc.
Via GlobeNewswire
Aflibercept 8 mg and EYLEA® (aflibercept) Injection Presentations at ARVO Provide New Insights into the Treatment of Serious Retinal Diseases
From Regeneron Pharmaceuticals, Inc.
Via GlobeNewswire
Regeneron Announces Investor Conference Presentations
From Regeneron Pharmaceuticals, Inc.
Via GlobeNewswire
Regeneron to Report First Quarter 2023 Financial and Operating Results and Host Conference Call and Webcast on May 4, 2023
From Regeneron Pharmaceuticals, Inc.
Via GlobeNewswire
Libtayo® (cemiplimab) in Combination with Chemotherapy Approved by European Commission for the First-line Treatment of Advanced PD-L1 Positive Non-small Cell Lung Cancer (NSCLC)
From Regeneron Pharmaceuticals, Inc.
Via GlobeNewswire
Sonoma Biotherapeutics and Regeneron Announce Collaboration to Discover, Develop and Commercialize Treg Cell Therapies for Autoimmune Diseases
From Sonoma Biotherapeutics, Inc.
Via Business Wire
Regeneron and Sonoma Biotherapeutics Announce Collaboration to Discover, Develop and Commercialize Treg Cell Therapies for Autoimmune Diseases
Sonoma Biotherapeutics to receive $75 million upfront, inclusive of $45 million cash and $30 million equity investment; potential for an additional $45 million development milestone payment 
From Regeneron Pharmaceuticals, Inc.
Via GlobeNewswire
Sanofi, Regeneron Shares Pop On Big News About COPD Treatment
Sanofi and Regeneron bolted higher on news about their jointly developed COPD medication Dupixent. Analysts say sales may hit $20 billion within a decade. 
Via MarketBeat
Dupixent® (dupilumab) Demonstrates Potential to Become First Biologic to Treat COPD by Showing Significant Reduction in Exacerbations in Pivotal Trial
From Regeneron Pharmaceuticals, Inc.
Via GlobeNewswire
FDA Approves First-in-class Evkeeza® (evinacumab-dgnb) for Young Children with Ultra-rare Form of High Cholesterol
From Regeneron Pharmaceuticals, Inc.
Via GlobeNewswire
Dupixent® (dupilumab) Approved by European Commission as First and Only Targeted Medicine for Children as Young as Six Months Old with Severe Atopic Dermatitis
From Regeneron Pharmaceuticals, Inc.
Via GlobeNewswire
Dupixent® (dupilumab) Late-Breaking Data at AAD Show Significant Improvements in Signs and Symptoms of Moderate-to-severe Atopic Hand and Foot Dermatitis
From Regeneron Pharmaceuticals, Inc.
Via GlobeNewswire
Students Win More Than $1.8 Million at 2023 Regeneron Science Talent Search for Remarkable Scientific Research on RNA Molecule Structure, Media Bias, and Diagnostics for Pediatric Heart Disease
$250,000 top award goes to Neel Moudgal in the nation’s oldest and most prestigious science and math competition for high school seniors 
From Regeneron Pharmaceuticals, Inc.
Via GlobeNewswire
Dupixent® (dupilumab) Application for Treatment of Chronic Spontaneous Urticaria (CSU) in Adults and Adolescents Aged 12 Years and Older Accepted for FDA Review
More than 300,000 people in the U.S. suffer from CSU that is inadequately controlled by antihistamines 
From Regeneron Pharmaceuticals, Inc.
Via GlobeNewswire
Kevzara® (sarilumab) Approved by FDA as First and Only Biologic Indicated for Patients with Polymyalgia Rheumatica
From Regeneron Pharmaceuticals, Inc.
Via GlobeNewswire
Libtayo® (cemiplimab) in Combination with Chemotherapy Receives Positive CHMP Opinion for the Treatment of Advanced PD-L1 Positive Non-small Cell Lung Cancer (NSCLC)
Recommendation based on a Phase 3 trial demonstrating superior survival outcomes for Libtayo plus chemotherapy compared to chemotherapy alone 
From Regeneron Pharmaceuticals, Inc.
Via GlobeNewswire
Aflibercept 8 mg BLA for Treatment of Wet Age-Related Macular Degeneration and Diabetic Macular Edema Accepted for FDA Priority Review
From Regeneron Pharmaceuticals, Inc.
Via GlobeNewswire
< Previous 1 2 Next >
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.